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OBJECTIVE — To determine the prevalence of subnormal testosterone concentrations in
patients with obesity and with type 2 diabetes in a primary care clinic population.
RESEARCH DESIGN AND METHODS — Free testosterone concentrations of 1,849
men (1,451 nondiabetic and 398 diabetic) in the Hypogonadism In Males (HIM) study were
analyzed. The HIM study was a U.S.-based cross-sectional study designed to deﬁne the preva-
lence of hypogonadism in men aged 45 years. Free testosterone was measured by equilibrium
dialysis.
RESULTS — The prevalence of subnormal free testosterone concentrations in lean, over-
weight, and obese nondiabetic men was 26% (n  275), 29% (n  687), and 40% (n  489),
respectively (P  0.001 for trend), and 44% (n  36), 44% (n  135), and 50% (n  227),
respectively, in diabetic men (P  0.46 for trend within group and P  0.05 compared with
nondiabetic men). The mean free testosterone concentration of diabetic men was signiﬁcantly
lower than that of nondiabetic men. Free testosterone concentrations were negatively and sig-
niﬁcantly (P  0.001) related to age (r  0.37), BMI (r  0.18), and sex hormone–binding
globulin (r  0.11) in multiple regression analysis. The average decline of free testosterone
concentrations was 7.8 pg/ml per decade in nondiabetic men and 8.4 pg/ml per decade in
diabetic men.
CONCLUSIONS — Forty percent of obese nondiabetic men and 50% of obese diabetic men
aged 45 years have subnormal free testosterone concentrations. In view of its high prevalence,
obesity is probably the condition most frequently associated with subnormal free testosterone
concentrations in males. The concomitant presence of diabetes is associated with an additional
increase in the prevalence of subnormal free testosterone concentrations.
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W
e have previously shown that
men with type 2 diabetes have a
high prevalence of hypogonado-
tropic hypogonadism (1). In these pa-
tients, there was a signiﬁcant inverse
relationshipofBMIwithtotalandfreetes-
tosterone concentrations (1,2). Our ob-
servations on the inverse relationship of
BMI and testosterone concentrations in
patients with type 2 diabetes have been
conﬁrmed in other studies (3,4). In an-
other study we found that BMI and total
testosterone and free testosterone con-
centrations were also inversely related in
type1diabeticmenwhorarelyhadhypo-
gonadism (5). These observations raise
the question whether obesity itself is as-
sociated with low free testosterone.
Studies in the past have suggested
that total testosterone concentrations are
lowerinobesementhaninmenwithnor-
malBMI(6).TheHypogonadismInMales
(HIM) study, which conﬁrmed the pres-
enceoffrequentlowtestosteroneconcen-
trations in men with diabetes (7) also
showedthattherewasatendencyfortotal
testosterone concentrations to be low in
patients with higher BMI. However, sex
hormone–binding globulin (SHBG) con-
centrations are also low in obese and dia-
betic men. According to the Endocrine
SocietyGuidelines,thediagnosisofhypo-
gonadism should be dependent on the
measurement of free testosterone or bio-
available testosterone in conditions that
can alter SHBG concentrations (8). Free
testosterone concentrations should be
measured by equilibrium dialysis or cal-
culatedusingalgorithmsbasedonthelaw
of mass action and the methods of Ver-
meulenetal.(9).Somepreviousrelatively
smallstudiesshowedthatBMIisinversely
related to total testosterone, SHBG, and
free testosterone but that only morbid
obesity (BMI 40 kg/m
2) was associated
with subnormal free testosterone concen-
trations (10–12). Recent studies have ex-
amined the prevalence of hypogonadism
in obesity in a much larger number of
men. One of these studies is the above-
mentioned HIM study. It was designed to
determine the prevalence of hypogonad-
ism (deﬁned as low total testosterone) in
men in the U.S. aged 45 years. This
study, which included 2,165 men,
showed that 38.7% of men had a subnor-
mal total testosterone concentration and
that 52% of the obese men and 50% of
diabetic men had subnormal total testos-
teroneconcentrations.However,thepub-
lication did not address free testosterone
concentrations in men with obesity, with
or without diabetes. A recently published
Dutch study in 149 obese men (mean age
43years)showeda36%prevalenceofhy-
pogonadotropic hypogonadism (13).
Men with diabetes were included in the
obesepopulationinboththeHIMandthe
Dutch studies; 23% of the study subjects
in the HIM study and 37% in the Dutch
study had diabetes. Data on nondiabetic
obese men were not reported separately.
Large studies on the prevalence of low
free testosterone in nondiabetic obese
men are thus not available, nor are any
data available on the differences in the
prevalenceofsubnormalfreetestosterone
concentrations in nondiabetic obese men
compared with those in diabetic men. Al-
thoughtheconcentrationoffreetestoster-
one falls with increasing obesity in
diabetic men, 25% of type 2 diabetic men
havesubnormalfreetestosteroneconcen-
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weight (1).
Because of the rising prevalence of
obesity in the U.S. and the rest of the
world, it is imperative that the prevalence
of low free testosterone in obese men be
deﬁned. Furthermore, the magnitude of
the contribution of obesity to subnormal
free testosterone associated with type 2
diabetes needs to be quantitated. To an-
swer these issues, we analyzed free testos-
terone concentrations in the obese
nondiabetic and diabetic men in the HIM
study. The hypotheses tested were that 1)
obese men have a higher prevalence of
subnormal free testosterone concentra-
tions than nonobese men and 2) that men
with diabetes have a higher prevalence of
subnormal free testosterone concentra-
tions than nondiabetic men, both obese
and nonobese.
RESEARCH DESIGN AND
METHODS— The HIM study re-
cruited 2,165 men in 95 centers across
the U.S. Study criteria have been pub-
lished previously (7). In brief, all men
aged45yearshadabloodsampletaken
in the morning (between 8:00 A.M. and
noon). Blood was analyzed for concentra-
tions of total testosterone, free testoster-
one,bioavailabletestosterone,andSHBG.
Total testosterone and SHBG were deter-
mined by radioimmunoassay, free testos-
terone by equilibrium dialysis, and
bioavailable testosterone by the ammo-
nium sulfate precipitation method (Eso-
terix, Calabasas Hills, CA). The lower
limit for free testosterone of the reference
laboratory was 50 pg/ml (0.174 nmol/l).
The lower limit for bioavailable testoster-
one was 90 ng/dl (0.313 nmol/l).
The HIM study had 474 men with
self-reported diabetes; 1,691 men did not
have diabetes. Judging by their medica-
tionlists,weexcludedmenwhoweretak-
ing antiretroviral drugs (33 men),
narcotics (78 men), or testosterone re-
placement therapy (33 men). We also ex-
cluded men currently using steroids,
narcotics, antibiotics (to eliminate men
with acute illnesses), or drugs that affect
thedopaminergicpathway(34men).The
prevalence of low free testosterone in all
these excluded men (n  178) was 50%.
Men with missing data on BMI or hor-
mone concentrations were also excluded
fromanalysis(n138).Wereportonthe
ﬁndings from 1,849 men, 398 of whom
had diabetes.
Group comparisons were performed
by one-way ANOVA, t tests, Mann-
Whitney rank sum tests, and 
2 tests as
appropriate. Data that were not normally
distributed were log-transformed to per-
form the parametric statistical tests. Total
testosterone, free testosterone, bioavail-
able testosterone, SHBG, age, and BMI
were not normally distributed and were
log-transformed. Pearson correlation and
multiple linear regression analyses be-
tween variables were done using Sigma-
Stat software (SPSS, Chicago, IL). Using
the statistical program SYSTAT-12, we
ran a stepwise regression with a forward
andbackwardsteppinggeneralizedlinear
model analysis to ﬁnd out the equation
that relates the effects of BMI and age in
diabetic and nondiabetic men on free tes-
tosterone levels. Adjustment for age and
BMIingroupcomparisonswasdonewith
ANCOVA and generalized linear model
analysis. For purposes of uniformity in
comparisons, data were adjusted to the
mean age (60.9 years) and BMI (29.7 kg/
m
2) of the whole population. Data are
presented as means  SD.
RESULTS— Thirty-ﬁve percent of all
men had subnormal free testosterone
concentrations, irrespective of diabetes
status. The mean age, BMI, and hormone
concentrations of diabetic and nondia-
betic men are shown in Table 1. The
crude prevalence of subnormal free tes-
tosterone concentrations in diabetic and
nondiabetic men was 51 and 31%, re-
spectively. Diabetic men were older and
heavier than nondiabetic men. Even after
adjustment for age and BMI, the preva-
lence of subnormal free testosterone con-
centrations in the diabetic men was
higherthanthatinnondiabeticmen(45%
vs. 33%). As expected, there was an in-
creaseintheprevalenceofsubnormalfree
testosteroneconcentrationswithage.Fig-
ure 1 shows the prevalence of subnormal
free testosterone concentrations in study
subjects divided into quartiles of age.
Prevalence of subnormal free
testosterone in lean, overweight, and
obese men
We analyzed the hormonal concentra-
tions of study subjects after stratifying
them in lean (BMI 25 kg/m
2), over-
weight (BMI 25–29.9 kg/m
2), and obese
(BMI 30 kg/m
2) categories (Table 1).
The data were adjusted for age and SHBG
differences. There was a signiﬁcant de-
cline in free testosterone concentrations
with BMI in both nondiabetic and dia-
betic men. Free testosterone concentra-
tions in lean, overweight, and obese
nondiabetic men were 62.0  19.4 pg/ml
(0.215  0.067 nmol/l), 60.9  19.3
pg/ml (0.211  0.067 nmol/l), and
55.519.7pg/ml(0.1930.068nmol/
l), respectively (P  0.001 by ANOVA).
Free testosterone concentrations in lean,
overweight, and obese diabetic men were
58.819.5pg/ml(0.2040.068nmol/
l), 56.9  19.5 pg/ml (0.198  0.068
nmol/l),and50.719.4pg/ml(0.176
0.068nmol/l),respectively(P0.002by
ANOVA).
The prevalence of subnormal free tes-
tosterone concentrations was 26% in
lean, 29% in overweight, and 40% in
obese nondiabetic men, whereas it was
44, 44, and 50% in lean, overweight, and
obesediabeticmen,respectively.Diabetic
men had a signiﬁcantly higher prevalence
ofsubnormalfreetestosteroneconcentra-
tions in all BMI categories (Table 1). Sim-
ilarresultswereobtainedwhenhormonal
concentrations were log-transformed and
compared (supplementary Table 2, avail-
able in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc09-
1649/DC1).
Fifty-onenondiabeticand57diabetic
men were morbidly obese (BMI 40 kg/
m
2). The mean free testosterone concen-
trations in morbidly obese nondiabetic
anddiabeticmenwere51.119.4pg/ml
(0.177  0.067 nmol/l) and 45.1  19.4
pg/ml (0.157  0.067 nmol/l), respec-
tively (P  0.15 by t test). The prevalence
of subnormal free testosterone in mor-
bidlyobesenondiabeticanddiabeticmen
was 49 and 55% (P  0.09 by 
2 test),
respectively.
Relation of free testosterone with age
and BMI
Free testosterone concentrations were
signiﬁcantly (P  0.001) and negatively
related to age (r  0.38) and BMI (r 
0.10).Theﬁnalequationthatdescribed
the decline in free testosterone (FT) con-
centrations with an increase in age and
BMI in nondiabetic men was
FT  123.57  0.7815  age 
0.5761  BMI
where free testosterone is in picograms
per milliliter, age is in years, and BMI is
weightinkilogramsdividedbythesquare
of height in meters.
In diabetic men, the equation was
FT  123.57  0.8382  age 
0.5761  BMI
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terone concentration with age in nondia-
betic and diabetic men was 7.8 and 8.4
pg/ml per decade, respectively. The aver-
agereductioninfreetestosteroneconcen-
tration if the BMI of the subject increases
by 1 kg/m
2 was 5.76 pg/ml in both dia-
betic and nondiabetic men.
Free testosterone concentrations
were negatively related to SHBG (r 
0.18, P  0.001). Age was negatively
related to BMI (r  0.16, P  0.001)
and positively to SHBG (r  0.34, P 
0.001). BMI was negatively related to
SHBG (r  0.28, P  0.001). We per-
formedmultiplelinearregressionanalysis
in a model with free testosterone as the
dependent variable and age, BMI, and
SHBG as the independent variables. Age,
BMI,andSHBGwereallindependentpre-
dictors of serum free testosterone (R
2 of
the model was 0.18; standardized [] co-
efﬁcients for age, BMI, and SHBG were
0.37, 0.18, and 0.11).
Wealsoanalyzedtheeffectofageand
BMI separately in lean, overweight, and
obese diabetic and nondiabetic men. The
results are presented in Fig. 2. These data
show that the relationship of free testos-
terone with age was stronger in the non-
obese men. On the contrary, the
relationship of free testosterone with BMI
was strongest in obese men.
Prevalence of subnormal free
testosterone in diabetic men taking
oral hypoglycemics and insulin
Of 398 men with diabetes, 67 were diet
controlled with diet, 201 were taking
metformin, 204 were taking sulfonyl-
ureas, 120 were taking thiazolidinedi-
ones, and 60 were taking insulin (insulin
monotherapy in 17 and insulin in combi-
nation with oral hypoglycemic drugs in
43).Theprevalenceofsubnormalfreetes-
tosterone was similar (P  0.40 by 
2)i n
men treated with diet (45%), metformin
(47%), sulfonylureas (54%), thiazol-
idinediones (48%), and insulin (57%),
whether alone or in combination with
oral agents.
Bioavailable testosterone
Log-transformed bioavailable testoster-
oneconcentrationswerelowerindiabetic
men than in nondiabetic men (supple-
mentary Table 2). Serum bioavailable
testosterone concentrations were inde-
pendently predicted by age, BMI, and
SHBG (R
2 of the model was 0.31;  coef-
ﬁcients for age, BMI, and SHBG were
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BMI-, and SHBG-adjusted prevalence of
subnormal bioavailable testosterone con-
centrations in diabetic and nondiabetic
men was 51 and 43%, respectively (P 
0.004).Theprevalenceofsubnormalbio-
available testosterone concentrations in
obese nondiabetic men (52%) was higher
than that in lean (37%, P  0.001) and
overweight (38%, P  0.001) nondia-
betic men. The prevalence of subnormal
bioavailable testosterone concentrations
in obese diabetic men (58%) was higher
than that in overweight (49%, P  0.05)
but not lean (51%, P  0.42) diabetic
men.
Prevalence of subnormal total
testosterone concentrations
The prevalence of subnormal total testos-
terone concentrations (300 ng/dl or
10.4nmol/l)was33%innondiabeticmen
and 44% in diabetic men (P  0.001 by

2test)afteradjustmentforage,BMI,and
SHBG concentrations. Thiry percent of
lean, 29% of overweight, and 39% of
obese nondiabetic men had subnormal
total testosterone concentrations (P 
0.001 by 
2 test). Thirty-three percent of
lean, 44% of overweight, and 46% of
obese diabetic men had subnormal total
testosterone concentrations (P  0.56 by

2 test). Serum total testosterone concen-
trations were independently predicted by
age, BMI, and SHBG (R
2 of the model was
0.45;  coefﬁcients for age, BMI, and
SHBG were 0.30, 0.16, and 0.65).
The age, BMI, and hormonal concentra-
tions of men with subnormal total testos-
terone, free testosterone, or both are
compared in supplementary Table 3
(available in an online appendix).
CONCLUSIONS— In this study, the
largest analysis undertaken to deﬁne the
prevalenceofsubnormalfreetestosterone
concentrations in obese men, the data
show clearly that 40% of all obese nondi-
abetic men and 49% of morbidly obese
nondiabetic men had subnormal free tes-
tosterone concentrations. Furthermore,
therewasaninverserelationshipbetween
free testosterone concentrations and BMI.
AccordingtotheNationalHealthandNu-
trition Examination Survey (NHANES)
2003–2004 data, 31% of all adult men in
U.S. are obese and 2.8% are morbidly
obese (14). Thus, in view of the fact that
almost one-third of the U.S. population is
obese, these observations have profound
pathophysiological, clinical, epidemio-
logical, and public health implications.
This study is also the ﬁrst to comprehen-
sively assess the comparative prevalence
ofsubnormalfreetestosteroneconcentra-
tions with obesity and diabetes separately
and together when they coexist.
Our study shows that diabetic men
with and without obesity have lower free
testosterone concentrations than nondia-
beticmenafteradjustmentforageorBMI.
The effect of having diabetes on the free
testosterone concentration in a 60-year-
old man was similar to that of an increase
inBMIof6kg/m
2(equaltoweightgainof
25 kg in a 180-cm [6-feet] tall man) in a
man without diabetes. The elevated insu-
lin resistance of type 2 diabetic men com-
paredwiththatofobesemenmayexplain
these ﬁndings. Cross-sectional analysis of
the NHANES III data (101 diabetic and
1,312 nondiabetic men) has shown that
low androgens are associated with the
presence of diabetes in men (15). The
prevalence of low free testosterone con-
centrations was not mentioned in that
analysis. The mean calculated free testos-
terone concentrations were similar in di-
abetic and nondiabetic men. We found a
small (6%) but statistically signiﬁcant dif-
ference in the age- and BMI-adjusted free
testosterone concentrations of diabetic
and nondiabetic men. The larger number
of diabetic subjects in our study might
explainthedifferenceinourdataandthat
fromNHANESIII.ThemeanageandBMI
of NHANES III subjects (57 years and
29.5 kg/m
2) were lower than those of our
diabetic study subjects. Consistent with
the NHANES III study, we did not ﬁnd a
difference in SHBG concentrations of di-
abetic and nondiabetic men.
The prevalence of low free testoster-
one in diabetic men was higher in all BMI
categories compared with that in nondia-
betic men. Whereas nondiabetic men
showed an increase in prevalence of sub-
normal free testosterone across BMI cate-
gories, there was no signiﬁcant change in
the prevalence of low free testosterone
with increasing BMI in the diabetic men.
This is attributable to the high prevalence
of low free testosterone in lean diabetic
men (45% after adjustment for age). Nev-
ertheless, we found that free testosterone
concentrations decreased signiﬁcantly
with increasing BMI in both diabetic and
nondiabetic men. In the morbidly obese
subjects, we found that there was a non-
signiﬁcant trend toward lower free tes-
tosterone concentrations and higher
prevalenceofsubnormalfreetestosterone
in diabetic men compared with that in
nondiabetic men. This could be due to
Figure 1—The prevalence of subnormal free testosterone (FT) concentrations in diabetic (DM,
u) and nondiabetic (non-DM, f) men separated into quartiles of age. Quartile 1 (aged 45–52
years) had 408 nondiabetic and 55 diabetic men. Quartile 2 (aged 53–59 years) had 378 nondi-
abetic and 82 diabetic men. Quartile 3 (aged 60–68 years) had 326 nondiabetic and 136 diabetic
men.Quartile4(aged69–91years)had339nondiabeticand125diabeticmen.Theprevalenceof
subnormal free testosterone concentrations was calculated in each quartile for nondiabetic and
diabetic men. The prevalence was then adjusted to the mean BMI (29.7 kg/m
2) of the whole study
population. A 
2 test was used to compare the prevalence among groups. A similar percentage of
nondiabeticanddiabeticmeninquartile1hadsubnormalfreetestosterone(18vs.18%,P0.97).
Nondiabetic men had a lower prevalence of subnormal free testosterone than diabetic men in the
other three quartiles (quartile 2, 22 vs. 41%, P  0.01; quartile 3, 32 vs. 50%, P  0.01; and
quartile 4, 58 vs. 67%, P  0.05).
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in the study (51 diabetic and 57
nondiabetic).
Free testosterone concentrations
were negatively related to age in our
study. We found that obese men had a
smaller age-related decline of free testos-
terone concentrations compared with
that in nonobese men. This result sug-
gestsanindependenteffectofBMI-related
factors on free testosterone concentra-
tions. Although our study cannot answer
questionsaboutthecausesoflowfreetes-
tosterone in the obese and type 2 diabetic
men, several prior studies have addressed
this question (10,12,16).
Ithasbeensuggestedthattheincrease
in adipose tissue mass in obesity may re-
sult in increased aromatase activity and
thusleadtoagreaterconversionoftestos-
terone into estradiol (12). An increase in
estradiolconcentrationswouldleadtothe
suppression of hypothalamic gonado-
tropin-releasing hormone and pituitary
gonadotropin secretion. This would re-
sult in the reduction of both testosterone
secretion by Leydig cells and spermato-
genesis in the seminiferous tubules.
Young overweight and obese men are in-
deed known to have a decrease in sperm
count (17). However, there hitherto has
been no study demonstrating that estra-
diol concentrations are actually elevated
in obese or diabetic patients with subnor-
mal testosterone concentrations. If in-
deed, this result is conﬁrmed, aromatase
inhibition could be a therapeutic strategy
in future. Unfortunately, estradiol con-
centrations are not available in our study.
The other possible mechanism in-
volved in the pathogenesis of obesity-
related low free testosterone is insulin
resistance. The selective deletion of the
insulin receptor gene from neurons re-
sults in a syndrome of hypogonadotro-
phichypogonadisminmiceinadditionto
a state of systemic insulin resistance (16).
It is therefore possible that insulin resis-
tance at the hypothalamic level contrib-
utestothepathogenesisofthissyndrome.
The concurrent presence of marked in-
ﬂammation may contribute to insulin re-
sistance because inﬂammatory mediators
suchastumornecrosisfactor-	andinter-
leukin-6 may interfere with insulin signal
transduction (18). Clearly, further inves-
tigation is necessary to deﬁne the etiology
of this syndrome.
In view of the increasing prevalence
of obesity even in younger populations, it
would be important to conduct a similar
studyinyoungindividualsattheprimeof
theirreproductiveyears.Itisrelevantthat
the prevalence of hypogonadotropic hy-
pogonadism is greater than 50% in pa-
tients with type 2 diabetes aged between
18 and 35 years (19).
We also found that SHBG concentra-
tions are negatively related to BMI and
positively to age. SHBG concentrations
decrease with insulin resistance, and low
SHBGconcentrationsarepredictiveoffu-
ture development of type 2 diabetes (20).
Althoughthisﬁndinghasbeenwellestab-
Figure 2—A: Inverse relationship of age with free testosterone concentration in nondiabetic
(non-DM, f) lean (r  0.53, P  0.001), overweight (r  0.43, P  0.001), and obese (r 
0.28, P  0.001) men. Thus, although age could explain 
25% of variability (R
2) in free
testosterone concentrations in nonobese individuals, it accounted for a signiﬁcantly lower vari-
ability (8%) in free testosterone in obese nondiabetic men (P  0.008). DM, u, diabetic men. B:
Inverse relationship of age with free testosterone in lean (U, r  0.57, P  0.001), overweight
(E, r  0.49, P  0.001), and obese (ƒ, r  0.30, P  0.001) diabetic men. Thus, although
age could explain 25–30% of variability (R
2) in free testosterone concentrations in nonobese
individuals, it accounted for a signiﬁcantly lower variability (9%) in free testosterone in obese
diabetic men (P  0.05 compared with nonobese men). C: Relationship of free testosterone with
BMI in lean (U, r  0.01, P  0.9), overweight (E, r  0.08, P  0.04), and obese (ƒ, r 
0.10,P0.03)non-diabeticmen.D:RelationshipoffreetestosteronewithBMIinlean(U,r
0.13, P  0.5), overweight (E, r  0.03, P  0.8), and obese (ƒ, r  0.17, P  0.01) diabetic
men.
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iological mechanisms behind these
associationsarenotknownandneedtobe
explored in future studies.
One of the limitations of our study is
that we could not differentiate between
type 1 and type 2 diabetes in our study
subjects. The presence of diabetes was re-
corded by a physician. However, because
90% of diabetic individuals have type 2
diabetesandthisnumberisevenhigherin
those aged 45 years, this issue is not
likely to affect the overall conclusions of
this study. We have previously shown
that the prevalence of hypogonadism
in type 1 diabetes is markedly lower than
that in type 2 diabetes (5). Only 17 pa-
tients were receiving insulin mono-
therapy, and thus they may have type 1
diabetes. Excluding these men did not
change the results of the study.
It is well known that there is a signif-
icant day-to-day variability in hormone
concentrations, especially testosterone.
As for most epidemiological or cross-
sectional studies, the testosterone con-
centrations in the HIM study were
measured only once. In view of the vari-
ability in testosterone concentrations,
this is a limitation. However, it is not
likely that the prevalence of low testos-
terone concentrations would have been
alteredafterrepeatedmeasurementsbe-
cause the probability of testosterone
concentrations rising or falling with re-
peated measurements is statistically
equal. The issue of repeated measure-
ments is important in the context of di-
agnosing hypogonadism clinically in
the context of a single patient. The fact
that our study included a moderately
large number of participants also helps
to diminish the effect of hormonal vari-
ability on study effects and the relation-
ship with BMI.
Wedidnothaveavalidatedquestion-
naire for erectile dysfunction and symp-
toms of hypogonadism. Therefore, we
cannot comment on the frequency of
symptomatichypogonadisminourstudy.
It has been shown in the past that a high
percentage of diabetic men with low tes-
tosterone concentrations have symptom-
atic hypogonadism (3,21). Lower
testosterone concentrations are inversely
related to visceral adiposity (3,22). How-
ever, waist circumference or body com-
position imaging was not available in our
study. Another limitation of our study is
that the subjects were not required to be
fasting when providing blood samples. It
has recently been shown that an oral glu-
cose load of 75 g can acutely lower total
testosterone concentrations by 25% (23).
However, in a prior analysis of these data,
no difference was found in total testoster-
one concentrations from blood samples
drawn between 8 A.M. and 10 A.M. vs. 10
A.M. and 12:00 P.M. (7).
In conclusion, 40% of obese nondia-
betic men, aged 45 years have subnor-
malfreetestosteroneconcentrations;26%
of normal-weight nondiabetic men and
44% of normal-weight diabetic men had
subnormal free testosterone concentra-
tions. The combination of obesity and
diabetes increases the prevalence of sub-
normal free testosterone concentrations
to 50%. Thus, both obesity and diabetes
appeartoexertindependenteffectsonthe
prevalence of low free testosterone con-
centrations in addition to age. In view of
the high rates of prevalence of subnormal
free testosterone in patients with obesity
or diabetes, concentrations of free testos-
terone should be measured in these pop-
ulations especially when these conditions
occur concomitantly.
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